## 1 Title Page

- 2 Title: Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary
- 3 attack rate: evidence from a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, January-
- 4 March 2021
- 5 **Authors:** Emily Dorothee Meyer<sup>\*1,2,3</sup>, Mirco Sandfort<sup>1,2,3</sup>, Jennifer Bender<sup>3,4,5</sup>, Dorothea Matysiak-
- 6 Klose<sup>6</sup>, Achim Dörre<sup>1</sup>, Gerhard Bojara<sup>7</sup>, Konrad Beyrer<sup>8</sup>, Wiebke Hellenbrand<sup>6</sup>

#### 7 Affiliations

- 8 1. Department of Infectious Disease Epidemiology, Postgraduate Training for Applied Epidemiology
- 9 (PAE), Robert Koch Institute, Berlin, Germany
- 10 2. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease
- 11 Prevention and Control (ECDC), Stockholm, Sweden
- 12 3. These authors contributed equally to this article and share first authorship
- 4. Department of Infectious Diseases, Nosocomial Pathogens and Antibiotic Resistances Unit, Robert
   Keah Institute, Parlin, Communication, Communisticatio, Communicatio, Communication, Communication, Commun
- 14 Koch Institute, Berlin, Germany
- 15 5. European Programme for Public Health Microbiology Training (EUPHEM), European Centre for
- 16 Disease Prevention and Control (ECDC), Stockholm, Sweden
- 6. Department of Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin,Germany
- 19 7. Local Public Health Authority Osnabrück
- 20 8. Department of Infectious Diseases, Public Health Agency of Lower Saxony
- 21 \*Corresponding author: Emily Dorothee Meyer
- 22 Corresponding author email: <u>meyere@rki.de</u>

#### 23 Abstract

- A SARS-CoV-2 Alpha outbreak was detected in a nursing home after residents and staff had
- completed vaccination with BNT162b. In a retrospective cohort study, we estimated an age-
- adjusted vaccine effectiveness of 88% [95% confidence interval (95%CI) 41-98%] against
- 27 hospitalization/death. Ct values at diagnosis were higher with longer intervals since the
- second vaccination [>21 vs. ≤21 days: 4.82 cycles, 95%CI: 0.06-9.58]. Secondary attack rates
- were 67% lower in households of vaccinated [2/9 (22.2%)] than unvaccinated infected staff
- 30 [12/18 (66.7%); p=0.046]. Vaccination reduced the risk of severe outcomes, Ct values and
- 31 transmission, but not fully. Non-pharmaceutical interventions remain important for vaccinated
- 32 individuals.

#### 34 Text

#### 35 Background

36 While COVID-19 case-fatality was <0.1% in under-50-year-olds [1], it was 13% in outbreaks of SARS-37 CoV-2 in nursing homes from January 2020 to February 2021 in Germany [2]. Hence, nursing homes 38 were prioritized for COVID-19 vaccination which began in Germany in December 2020 [3]. We report 39 on a SARS-CoV-2 Alpha (B.1.1.7) outbreak among residents and staff of a nursing home in Germany, 40 of whom some were vaccinated with two doses of BNT162b. This study describes the epidemiology 41 of the outbreak, the undertaken control measures and the vaccine effectiveness (VE) against SARS-42 CoV-2 Alpha infections, disease and severe outcomes (hospitalization or death) and the vaccine 43 effects on viral load and secondary transmission.

#### 44 Study design

45 Cases were defined as residents (either permanent or day-care) or staff who had a positive SARS-46 CoV-2-PCR between early January 2021 (symptom onset of first case denoted as day 0) and mid-March 2021 (2 weeks after diagnosis of the last case, day 74). In a retrospective cohort study, we 47 48 included all residents and staff who attended the nursing home during the same time period. We 49 compared attack rates (AR) with Chi-squared or Fisher's exact tests. We estimated vaccine 50 effectiveness (VE) as VE=1-RR, where RR denotes the relative risk for the respective outcome in 51 vaccinated vs. unvaccinated individuals, calculated by Poisson regression. Considered outcomes were 52 SARS-CoV-2 infection, symptomatic infection and severe courses (defined as hospitalization or death 53 from COVID-19). Using linear regression, we analyzed the effect of the time interval between the 54 second vaccine dose and viral load at diagnosis (using Ct value for the ORF1AB gene at the first 55 positive PCR as a proxy). Unvaccinated cases were assigned an interval of 0 days. We assessed 56 secondary attack rates (SAR) among household members of SARS-CoV-2-positive staff, who were tested twice during their quarantine. One household outside the administrative district was excluded 57

58 because data was unavailable. Secondary cases were defined as SARS-CoV-2 PCR-positive household

59 members diagnosed 1-14 days after the diagnosis of the corresponding staff index case.

#### 60 Ethical statement

- 61 This outbreak investigation was conducted in accordance to paragraph 4 of the German Protection
- against Infection Act. Therefore, this investigation was exempt from additional institutional review.

#### 63 Study setting

- 64 The nursing home comprised one day-care and seven permanent care wards with 128 members of
- staff, 100 residents in permanent care and 24 persons in day-care. Ninety-five/124 (77%) residents
- and 72/128 (56%) staff members were vaccinated with BNT162b in early and late January 2021, with
- an inter-dose interval of three weeks. Median age was 49 years among staff (inter-quartile range
- 68 (Q25-Q75): 32-58) and 87 years among residents (Q25-Q75: 83-92). Among residents, 97/124 (77%)
- and among staff, 113/128 (88%) were female.

#### 70 Measures in place before the outbreak

All staff had to conduct daily rapid antigen detection tests (RADT). Residents were tested related to incidences, e.g. when becoming symptomatic. All visitors of the nursing homes could only enter with a negative RADT of the same day. Staff and visitors had to wear FFP2 standard masks inside the nursing home. Staff was assigned in teams to designated wards and rotation between wards was minimized. However, this was not possible for night shifts and social workers.

#### 76 The epidemiology of the outbreak

- After detecting the first SARS-CoV-2 infection in a permanent care resident in early February 2021
  (day 30) and previous, sporadic cases among four staff since early January 2021 (day 0), an outbreak
- 79 investigation was initiated. Between early January 2021 (day 0) and 14 days after the detection of the
- 80 last case in mid-March 2021 (day 74), 50 SARS-CoV-2 cases were detected, of which 35 were
- 81 symptomatic (70%; 16/35 (46%) vaccinated). Four residents (1/4 (25%) vaccinated) were hospitalized

and five died (2/5 (40%) vaccinated) from or with COVID-19. The crude AR among residents (AR=27%,
34/124) was higher than among staff (AR=12%, 16/128, p<0.01). Typing of PCR samples for variants</li>
of concern detected variant Alpha in 27/28 samples.

#### 85 The course of the outbreak

A kitchen staff, working in a kitchen serving all sections, developed symptoms on day 0, worked for two more days prior to isolation with no reported contacts to other care sections. Between day 8 and day 23, mainly the day-care was affected with nine detected cases (eight residents and one member of staff) and was therefore closed. In the stationary care, two members of staff developed symptoms on day 28 and a resident was RADT-positive on day 30. Subsequently, the outbreak spread in the permanent care wards, see Figure 1 and 2.

#### 92 Potential sources of the outbreak

93 All members of the vaccination team were tested negative with daily RADT and with weekly PCR. 94 Therefore, it seems unlikely that the vaccination team was the source of the outbreak. Initially, no 95 links between the day-care and the stationary care were reported. However, the contact tracing 96 information revealed that an external health-care worker (ID-5160, see Figure 3) visited a highly 97 infectious case (ID-2640, Ct value 11) from the day-care on day 10 and a person from the permanent 98 care (ID-870) on day 12 (who tested positive later), suggesting that they visited ID-870 within the 99 infectious period. ID-5160 was tested positive with an RADT on day 13. Potentially, the ID-5160 100 represents a link between these two sections. However, no sequencing data was available to further 101 delineate possible transmission chains. The other 165 visitors of the nursing home did not have 102 timely relevant SARS-CoV-2 infections and were therefore excluded as potential sources of 103 infections.

#### 104 Outbreak management

On day 32, 4 days after the first member of staff of the stationary care was symptomatic, regular PCR
serial testing was implemented for all residents and staff every 5 days until two consecutive PCR

serial tests had negative results only. All symptomatic or PCR-positive residents were isolated as a
cohort on a designated ward. Non-cases could move within their ward but contacts between wards
were minimized. Close contacts were quarantined in their rooms. Case isolation ended once cases
were asymptomatic and were PCR-negative at the earliest after 14 days. No visitors were allowed
between day 31 and day 74.

#### 112 Vaccine effectiveness

113 Among 29 vaccinated cases, the date of diagnosis (defined as the earlier date of either symptom-114 onset or sampling of a positive test) was 7-11 days after the second vaccine in 14 cases (48%, all 115 residents), while 15 (52%) were diagnosed 20 or more days post vaccination. SARS-CoV-2 infections 116 were diagnosed less frequently among vaccinated than unvaccinated residents (Table 1, p=0.46) and 117 staff (Table 1, p=0.06). Age-adjusted VE  $\geq$ 7 days after two doses of BNT162b was 45% (0-69%, 118 p=0.048) against infection. Among residents and staff, vaccinated cases were less symptomatic than 119 unvaccinated cases (Table 1, residents: p=0.04, staff: p<0.01). Age-adjusted VE was 68% (36-84%; 120 p<0.01) against disease. Of 50 cases, four were hospitalized (1/4 (25%) vaccinated) and five (2/5 121 (40%) vaccinated) died (all residents). Age-adjusted VE ≥7 days after completed vaccination was 88% 122 (37-98%; p=0.01) against severe outcomes. 123 Age confounded the association between vaccination status and infection, disease and severe 124 outcomes, changing effect estimates by 21% (from 0.70 to 0.55), 20% (from 0.40 to 0.32) and 50% 125 (from 0.24 to 0.12), respectively (Table 2). Gender was not associated with risks for infection (p=0.64)

126 or disease (p=0.69), but women exhibited a lower risk for severe outcomes (p=0.07, Table 2),

however not after adjusting for age and vaccination status [RR=0.34, 95%CI: 0.06-1.85, p=0.20].

128 Among symptomatic cases, no association of the time interval between the second vaccine dose and

diagnosis with the risk for severe outcomes was observed (time in days: IRR=0.93, 95%CI: 0.76 - 1.06,

130 p=0.34; 7-14 days vs. >14 days: IRR=0.78, 95%CI:0.10-15.81, p=0.83), adjusted for age.

#### 131 Vaccination reduced the viral load

132 Ct values at diagnosis were on average 3.04 cycles (Table 3, p=0.28) higher among vaccinated than 133 unvaccinated cases. The Ct value increased with time since the second vaccine dose (Table 3 and 134 Figure 3). Age (p=0.79) and sex (p=0.61) was not associated with the Ct value (Table 3).

#### 135 Vaccination reduced secondary transmission in households

We analyzed 14 households of SARS-CoV-2-positive staff (five vaccinated, nine unvaccinated). We found two secondary cases in 1/5 (20%) households of vaccinated staff (index staff case was diagnosed 25 days after the second vaccination) and 12 secondary cases in 5/9 (56%) households of infected, unvaccinated staff. For calculating the adjusted SAR, we excluded household members with a PCR-confirmed SARS-CoV-2 infection <6 months prior or who quarantined separately from infected staff. Household members with a vaccinated index case had a lower SAR [2/9 (22%)] than household members of unvaccinated SARS-CoV-2-positive staff (p=0.046, Fisher's exact test, Table 4).

#### 143 Discussion

In our study, the age-adjusted VE of two doses of BNT162b was moderate against infection and 144 145 disease and high against severe COVID-19. Our VE estimates are lower than in a population-based 146 cohort study conducted in Israel [4] that reported a VE of 96% against hospitalization and 93% 147 against death. This can be explained by a higher potential for repeated contacts with infected cases 148 and a higher median age in this outbreak setting. Furthermore, half of the vaccinated cases were 149 diagnosed within 7-11 days after the second vaccination; thus, infection occurred prior to attaining 150 full immunity. However, we did not observe higher effectiveness among cases with a longer interval 151 between the second vaccine and diagnosis, in line with findings from the UK [5]. Our analysis is limited by the small sample size and inability to control for risk factors such as underlying chronic 152 153 diseases and compliance with protective measures. The individual risk of infection possibly changed 154 over time with the implementation of non-pharmaceutical control measures, such as separating 155 cases from non-cases, thereby potentially biasing the VE results of our study.

Our VE against infection was lower than in previous studies from similar settings [4], [6], [7]. Since this cohort was PCR-tested every 5-6 days throughout the outbreak, we believe that the risk for missing asymptomatic cases was minimal while in other studies under-ascertainment of asymptomatic infection may have occurred.

We found a significantly lower Ct value among vaccinated cases ≥21 days after the second vaccine (6 weeks after the first) than among non-vaccinated cases. One study assessing a similar study population [8] found lower viral loads already four weeks after the first vaccination. However, the authors pooled different Ct values from all available PCR-positive results, which may have impacted the inter-assay comparability [9], especially considering N-gene dropouts with the Alpha variant [10].

Our results suggest that while transmission was reduced, close contacts of vaccinated persons with break-through SARS-CoV-2 infections remained at risk for infection, as shown in previous studies for household members of healthcare workers vaccinated with BNT162b2 [11]. As no samples could be sequenced, our results are limited by the inability to show that primary and secondary cases had identical viral strains. Still, these results have strong implications for policy makers because they emphasize that adhering to non-pharmaceutical interventions is still very important for vaccinated people.

We believe that the regular PCR serial testing, isolating cases on a designated ward and quarantining close contacts of cases in their rooms contributed to the successful outbreak control. It is possible that the outbreak on the day-care and the stationary ward were linked via a visiting health-care worker. However, typing revealed that at least two different strains were present in this outbreak, suggesting two introductory events of SARS-CoV-2 at minimum.

#### 177 Conclusions

Two doses of BNT162b significantly reduced the risk for SARS-CoV-2 infections, symptomatic
infections, severe outcomes, viral load and secondary transmission, even within 14 days after the
second dose. However, the incomplete protection emphasizes that adhering to non-pharmaceutical

- 181 interventions remains important after completed vaccination. When reconsidering non-
- 182 pharmaceutical measures for fully vaccinated people, policy makers need to be aware that the risk
- 183 reduction for vaccination people regarding the risk for infection, severe outcomes and transmission is
- 184 incomplete. Regular PCR serial testing and isolation of cases on a designated ward contributed to the
- 185 outbreak control.

### 186 Acknowledgement

- 187 The authors are grateful for the work and the commitment of all public health staff throughout the
- 188 pandemic. The authors would like to specifically thank the Local Public Health Authority, Osnabrück,
- the Department of Infectious Diseases of the Public Health Agency of Lower Saxony, Hannover,
- 190 Germany and the staff of the affected nursing home for their cooperation in the investigation. Emily
- 191 Meyer, Mirco Sandfort and Jennifer Bender would like to thank their frontline coordinators Sybille
- 192 Rehmet, Katharina Alpers and Loredana Ingrosso for their continuous support.

#### 193 Financial support

- 194 EM and MS are fellows of the German postgraduate training for applied epidemiology (PAE). JB is a
- 195 fellow of the ECDC Fellowship Programme, supported financially by the European Centre for Disease
- 196 Prevention and Control (ECDC). This research received no specific grant from any funding agency,
- 197 commercial or not-for-profit sectors.

#### 198 Disclaimers

No conflict of interest reported. JB is a fellow of the ECDC Fellowship Programme. The views and
 opinions expressed herein do not state or reflect those of the ECDC. The ECDC is not responsible for
 the data and information collection and analysis and cannot be held liable for conclusions or opinions
 drawn.

#### 203 Data availability statement

- 204 Aggregated data from a limited version of the German notification system database can be retrieved
- via SurvStat@RKI 2.0 https://survstat.rki.de/. Detailed data are confidential and protected by
- 206 German law and are available from the corresponding author upon reasonable request.

#### 207 **References**

- 208 [1] Robert-Koch-Institut, "RKI Infektionskrankheiten A-Z Epidemiologischer Steckbrief zu SARS 209 CoV-2 und COVID-19", 2021.
- 210 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Coronavirus/Steckbrief.html;jsessionid=
- 211 8626D400296162979EAA91A303BC1216.internet072?nn=2386228 (accessed Jan. 11, 2021).
- 212 [2] B. Schweickert et al., "COVID-19-Ausbrüche in deutschen Alten- und Pflegeheimen
- 213 Hintergrund," *Epid Bull*, no. 18, pp. 3–29, 2021.
- 214 [3] S. Vygen-Bonnet et al., "Beschluss der STIKO zur 1. Aktualisierung der COVID-19-
- 215 Impfempfehlung und die dazugehörige wissenschaftliche Begründung STIKO-Empfehlung zur
- 216 COVID-19-Impfung " 2021. [Online]. Available:
- 217 https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/02\_21.pdf.
- 218 [4] E. J. Haas *et al.*, "Nationwide vaccination campaign with BNT162b2 in Israel demonstrates
- 219 high vaccine effectiveness and marked 3 declines in incidence of SARS-CoV-2 infections and
- 220 COVID-19 cases, hospitalizations, and deaths," [Online]. Available:
- 221 https://ssrn.com/abstract=3811387.
- 222 [5] B. JL et al., "Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and
- ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in
   older adults in England," Mar. 2021, doi: 10.1101/2021.03.01.21252652.
- 225 [6] M. S et al., "Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2
- infection in long-term care facilities in Spain," Apr. 2021, doi: 10.1101/2021.04.08.21255055.

- I. Rask Moustsen-Helms *et al.*, "Vaccine effectiveness after 1st and 2nd dose of the BNT162b2
   mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers-a Danish
- 229 cohort study Corresponding Author," Mar. 2021, doi: 10.1101/2021.03.08.21252200.
- 230 [8] M. Shrotri *et al.*, "Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2
- 231 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study)," doi:
- 232 10.1101/2021.03.26.21254391.
- 233 [9] C. Buchta *et al.*, "Variability of cycle threshold values in an external quality assessment
- 234 scheme for detection of the SARS-CoV-2 virus genome by RT-PCR," *Clin. Chem. Lab. Med.*, vol.
- 235 59, no. 5, pp. 987–994, Apr. 2021, doi: 10.1515/cclm-2020-1602.
- [10] P. Wollschlaeger *et al.*, "SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for
  the presence of B.1.1.7 lineage in a commercial multiplex PCR assay," *Clin. Microbiol. Infect.*,
  May 2021, doi: 10.1016/j.cmi.2021.05.025.
- 239 [11] R. J. Harris, J. A. Hall, A. Zaidi, N. J. Andrews, J. Kevin Dunbar, and G. Dabrera, "Impact of
- 240 vaccination on household transmission of SARS-COV-2 in England", 2021. [Online] Available:
- 241 https://pubmed.ncbi.nlm.nih.gov/34161702/, doi: 10.1056/NEJMc2107717

242

## 244 Tables

#### 245

## 246Table 1: Outcomes of a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, Jan-Mar 2021, stratified by247vaccination status among residents, staff and all.

	Vaccination		Case		Symptomatic		Hospitalization		Death		
		n	%	n	AR	n	% of cases	n	% of cases	n	% of cases
Residents	No	29		10	34%	8	80%	3	30%	3	30%
	Yes	95	77%	24	25%	13	54%	1	4%	2	8%
Staff	No	56		11	20%	11	100%	0	0%	0	0%
	Yes	72	56%	5	7%	3	60%	0	0%	0	0%
Total	No	85		21	25%	19	90%	3	14%	3	14%
	Yes	167	66%	29	17%	16	55%	1	3%	2	7%

248 Attack rate (AR) with the strata size as denominator. Symptomatic cases, hospitalization and deaths

249 with respective number of cases as denominator.

- 251 Table 2. Risk for SARS-CoV-2 infection, risk for symptomatic infection and risk for severe outcome (hospitalization or
- 252 death) during a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, Jan-Mar 2021.

		Risk for infection									
		Univari	Multivariable								
Variable		RR (95%CI)	p-value	RR (95%CI)	p-value						
Age	Years	1.02 (1.00-1.03)	0.01	1.02 (1.01-1.03)	< 0.01						
Sex	Female	0.85 (0.44-1.79)	0.64								
	Male	Ref									
Vaccination	Yes	0.70 (0.40-1.25)	0.22	0.55 (0.31-1.00)	0.048						
	No	Ref		Ref							
		I	Risk for symp	tomatic infection							
		Univari	ate	Multiv	variable						
		RR (95%CI)	p-value	RR (95%CI)	p-value						
Age	Years	1.01 (0.99-1.02)	0.24	1.02 (1.00-1.03)	0.04						
Sex	Female	0.84 (0.39-2.10)	0.69								
	Male	Ref									
Vaccination	Yes	0.40 (0.20-0.78)	< 0.01	0.32 (0.16-0.64)	< 0.01						
	No	Ref		Ref							
			Risk for se	vere outcome							
		Univari	ate	Multivariable							
		RR (95%CI)	p-value	RR (95% CI)	p-value						
Age	Years	1.11 (1.03-1.26)	< 0.01	1.12 (1.04-1.27)	< 0.001						
Sex	Female	0.21 (0.04-1.14)	0.07								
	Male	Ref									
Vaccination	Yes	0.24 (0.03-1.23)	0.09	0.12 (0.02-0.59)	0.01						
	No	Ref		Ref							

253 Estimates of risk ratios (RR) and 95% confidence intervals (CI) were calculated with uni- and

254 multivariable Poisson regression models. P-values from log-likelihood ratio test. Reference levels of

255 categorical variables are indicated by "Ref". Variables were included in a multivariate model if the

256 log-likelihood ratio test resulted in  $p \le 0.05$ .

Table 3: Associations with the Ct value of the PCR at diagnosis in a SARS-CoV-2 Alpha outbreak in a nursing home in
 Germany, Jan-Mar 2021.

Variable		Coefficient	95%CI	p-value
Age	Δ years	-0.02	-0.15 - 0.12	0.80
Sex	Female	1.53	-4.81 - 7.87	0.63
	Male	Ref		
Symptoms	No	6.32	1.89 - 10.75	<0.01
Symptoms	Yes	Ref		
Versignation	Yes	3.04	-2.86 - 8.93	0.30
Vaccination	No	Ref		
Time interval between second	Δ days	0.23	0.01 - 0.45	0.04
	> 14 days	3.53	-1.15 - 8.22	0.13
vaccine and diagnosis	≤ 14 days	Ref		
	> 21 days	4.82	0.06 - 9.58	0.047
	≤ 21 days	Ref		

259 The results were calculated with univariate linear regression models. Δ: indicates a numerical

260 variable. 95%CI: 95% confidence interval; P-values are based on Wald tests.

#### 262 Table 4: Secondary SARS-CoV-2 cases and secondary attack rate (SAR) in households of SARS-CoV2-positive staff,

263 stratified by vaccination status, during a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, Jan-Mar 2021.

Vaccination		Househo	Crude Analysis		Adjusted Analysis				
status of index	Tatal	Infected	Duina	Comonato	Tatal	ra /a NI	CAD	n /a di N	C A D
staff case	Total	Infected	Prior	Separate	Total	n/cN	SAR	n/adj.N	SAR
	(cN)	(n)	infection	isolation	(adj.N)				
Vaccinated	9	2	0	0	9	2/9	22%	2/9	22%
Unvaccinated	22	12	2	2	18	12/22	55%	12/18	67%
Total	31	14	2	2	27	14/31	45%	14/27	52%

264 cN: crude N, adj.N adjusted N; Adjusted SAR excludes household members infected within 6 months


prior to the infection of the staff index case and excludes household members who isolated

266 separately from the staff index case.

267

## 269 Figures


- 270 Figure 1: Timeline of events and measures during a SARS-CoV-2 Alpha outbreak in a nursing home
- *in Germany, Jan-Mar 2021*




- 275 Figure 2: Cases of SARS-CoV-2 Alpha by time of diagnosis during an outbreak in a nursing home in
- **276** *Germany, Jan-Mar 2021*
- 277 Color represents the area of residence or activity within the nursing home ("all" if no designation to a
- specific ward). Date of diagnosis defined as the earlier date of either symptom-onset or sampling of apositive test.
  - 10. Day-care closed 1st vaccination 2nd vaccination 8 Section Number of PCR-positive cases Kitchen 6 Day-care Ward 2 Ward 3 Ward 4 Ward 5 4 Ward 6 All 1 2 0. 25 30 35 Day of diagnosis relative to first case ò 10 15 45 50 55 5 20 40 60

281

- 282 Figure 3: Contact network of PCR-positive cases of a SARS-CoV-2 Alpha outbreak in a nursing home
- 283 *in Germany, Jan-Mar 2021*
- 284 Star: PCR typing: Alpha
- 285 Asterix: PCR typing: wild type
- 286 Question mark: No typing performed
- 287 Number below symbol: ID
- 288 Color represents the area of residence or activity within the nursing home or external visitors or
- 289 household members
- 290



# Figure 4: Ct-Value (ORF1AB gene) of the first positive PCR by interval between second vaccination and diagnosis during a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, Jan-Mar 2021



Unvaccinated on day 0